Repeated administration of recombinant human erythropoietin (rhEPO) causes upregulation of receptor-mediated tissue uptake by the spleen (Kato, M., H. Kamiyama, A. Okazaki, K. Kumaki, Y. Kato, and Y. Sugiyama. J. Pharmacol. Exp. Ther. 283: 520-527, 1997). To discover whether such upregulation is due to an increase in target cells, the numbers of colony-forming unit erythroids (CFU-E) and burst-forming unit erythroids (BFU-E), the precursor of CFU-E, were measured in the spleen after rhEPO treatment. The uptake clearance of ¹²⁵I-labeled rhEPO by the spleen was almost proportional to the number of CFU-E, suggesting that the upregulation is due to an increased number of CFU-E. When growth cells were metabolically labeled with [³H]thymidine in vivo, the radioactivity in bone marrow fell significantly after rhEPO treatment, whereas that in the spleen increased significantly. A cell-fractionation study using Percoll revealed that the radioactivity in the BFU-E fraction of splenic cells increased initially after rhEPO treatment, followed by an increase in radioactivity in the CFU-E fraction with a concomitant reduction in radioactivity in the BFU-E fraction. These results demonstrate that EPO stimulates the migration of BFU-E from bone marrow to spleen, followed by its differentiation into CFU-E in the spleen. In conclusion, the upregulation observed in the spleen is due to its stimulatory effect on the migration of BFU-E.

migration; receptor-mediated endocytosis; cytokine

This article has been cited by other articles:

				S. Chapel, P. Veng-Pedersen, R. J. Hohl, R. L. Schmidt, E. M. McGuire, and J. A. Widness Changes in Erythropoietin Pharmacokinetics following Busulfan-Induced Bone Marrow Ablation in Sheep: Evidence for Bone Marrow as a Major Erythropoietin Elimination Pathway J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 820 - 824. [Abstract] [Full Text] [PDF]